220 related articles for article (PubMed ID: 10519405)
1. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM
Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
3. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
5. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
[TBL] [Abstract][Full Text] [Related]
6. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
Lerner EC; Qian Y; Hamilton AD; Sebti SM
J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model.
Pollack IF; Bredel M; Erff M; Hamilton AD; Sebti SM
Neurosurgery; 1999 Nov; 45(5):1208-14; discussion 1214-5. PubMed ID: 10549939
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
Nakamura K; Yamaguchi A; Namiki M; Ishihara H; Nagasu T; Kowalczyk JJ; Garcia AM; Lewis MD; Yoshimatsu K
Oncol Res; 2001; 12(11-12):477-84. PubMed ID: 11939411
[TBL] [Abstract][Full Text] [Related]
9. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
[TBL] [Abstract][Full Text] [Related]
10. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
11. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
[TBL] [Abstract][Full Text] [Related]
12. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
Mazet JL; Padieu M; Osman H; Maume G; Mailliet P; Dereu N; Hamilton AD; Lavelle F; Sebti SM; Maume BF
FEBS Lett; 1999 Oct; 460(2):235-40. PubMed ID: 10544242
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
14. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner.
Vogt A; Sun J; Qian Y; Hamilton AD; Sebti SM
J Biol Chem; 1997 Oct; 272(43):27224-9. PubMed ID: 9341167
[TBL] [Abstract][Full Text] [Related]
15. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
Vogt A; Qian Y; Blaskovich MA; Fossum RD; Hamilton AD; Sebti SM
J Biol Chem; 1995 Jan; 270(2):660-4. PubMed ID: 7822292
[TBL] [Abstract][Full Text] [Related]
16. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
Sun J; Qian Y; Hamilton AD; Sebti SM
Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics.
Qian Y; Vogt A; Vasudevan A; Sebti SM; Hamilton AD
Bioorg Med Chem; 1998 Mar; 6(3):293-9. PubMed ID: 9568283
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity.
Henry KJ; Wasicak J; Tasker AS; Cohen J; Ewing P; Mitten M; Larsen JJ; Kalvin DM; Swenson R; Ng SC; Saeed B; Cherian S; Sham H; Rosenberg SH
J Med Chem; 1999 Nov; 42(23):4844-52. PubMed ID: 10579847
[TBL] [Abstract][Full Text] [Related]
19. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.
Peterson YK; Kelly P; Weinbaum CA; Casey PJ
J Biol Chem; 2006 May; 281(18):12445-50. PubMed ID: 16517596
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
Rose WC; Lee FY; Fairchild CR; Lynch M; Monticello T; Kramer RA; Manne V
Cancer Res; 2001 Oct; 61(20):7507-17. PubMed ID: 11606387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]